# Bioequivalence Study of Losartan Potassium (100 mg Tablet) [Test Formulation, Torrent Pharmaceuticals Ltd., India] Versus Cozaar® (100 mg Tablet) [Reference Formulation, Merck & Co. Inc., USA] in Healthy Human Volunteers Under Fed Condition

> **NCT01218698** · PHASE1 · COMPLETED · sponsor: **Torrent Pharmaceuticals Limited**

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Losartan Potassium Tablets

## Key facts

- **NCT ID:** NCT01218698
- **Lead sponsor:** Torrent Pharmaceuticals Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2017-10-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01218698

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01218698, "Bioequivalence Study of Losartan Potassium (100 mg Tablet) [Test Formulation, Torrent Pharmaceuticals Ltd., India] Versus Cozaar® (100 mg Tablet) [Reference Formulation, Merck & Co. Inc., USA] in Healthy Human Volunteers Under Fed Condition". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01218698. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*